PD-L1 in circulating exosomes of Merkel cell carcinoma.
Fiche publication
Date publication
janvier 2022
Journal
Experimental dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr GARRIDO Carmen, Dr GOBBO Jessica, Dr NARDIN Charlée
Tous les auteurs :
Zanella A, Vautrot V, Aubin F, Avoscan L, Samimi M, Garrido C, Gobbo J, Nardin C
Lien Pubmed
Résumé
Exosomes, as potential circulated biomarkers, have recently become a topic of interest in the field of oncology. Immune checkpoint molecule PD-L1 has recently been detected in circulating exosomes from cancer patients. The purpose of this work was to evaluate PD-L1 levels in circulating exosomes (Exo-PD-L1) isolated from patients' plasma suffering from Merkel cell carcinoma (MCC).
Mots clés
Merkel cell carcinoma, PD- L1, anti-PD L1, avelumab, biomarker, exosomes, immunotherapy
Référence
Exp Dermatol. 2022 Jan 7;: